Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCLNASDAQ:CDXCNASDAQ:DBVTNYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$3.81+1.5%$2.66$1.89▼$4.09$1.13B0.623.42 million shs1.95 million shsCDXCChromaDex$6.16$2.41▼$9.18$611.50M2.21816,251 shs554,788 shsDBVTDBV Technologies$11.54+12.0%$9.42$2.20▼$12.78$317.72M-0.59191,872 shs29,062 shsNUVBNuvation Bio$2.09+1.7%$2.14$1.54▼$3.97$711.15M1.332.96 million shs3.37 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics0.00%+5.40%+60.55%+82.06%+40.41%CDXCChromaDex0.00%0.00%0.00%0.00%+209.65%DBVTDBV Technologies0.00%+25.63%+34.96%+77.52%+203.66%NUVBNuvation Bio0.00%+7.36%-16.10%+25.60%-28.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.4724 of 5 stars3.41.00.00.03.23.30.0CDXCChromaDex3.2043 of 5 stars3.50.00.04.00.00.01.9DBVTDBV Technologies3.7508 of 5 stars4.43.00.00.02.62.50.6NUVBNuvation Bio3.4476 of 5 stars4.60.00.00.02.45.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.75Moderate Buy$8.33119.01% UpsideCDXCChromaDex 3.00Buy$9.03∞ UpsideDBVTDBV Technologies 2.80Moderate Buy$14.7527.83% UpsideNUVBNuvation Bio 3.20Buy$7.17243.73% UpsideCurrent Analyst Ratings BreakdownLatest DBVT, CDXC, NUVB, and ABCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$21.006/25/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.006/17/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$10.00 ➝ $6.006/11/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.006/2/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.005/29/2025DBVTDBV TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell$7.255/27/2025DBVTDBV TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/27/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.005/16/2025ABCLAbCellera BiologicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $10.005/15/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$28.83M39.39N/AN/A$3.58 per share1.06CDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00DBVTDBV TechnologiesN/AN/AN/AN/A$1.42 per shareN/ANUVBNuvation Bio$7.87M90.15N/AN/A$1.37 per share1.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/5/2025 (Estimated)CDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/ADBVTDBV Technologies-$113.92M-$4.92N/AN/AN/A-3,249.99%-278.24%-140.54%7/29/2025 (Estimated)NUVBNuvation Bio-$567.94M-$2.35N/AN/AN/A-5,534.21%-44.14%-32.97%8/4/2025 (Estimated)Latest DBVT, CDXC, NUVB, and ABCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025DBVTDBV Technologies-$0.28N/AN/AN/A$0.64 millionN/A5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million5/7/2025Q1 2025NUVBNuvation Bio-$0.16-$0.16N/A-$0.16$0.42 million$3.08 million4/11/2025Q4 2024DBVTDBV TechnologiesN/A-$1.10N/A-$1.10N/A$0.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/ACDXCChromaDexN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A10.1510.15CDXCChromaDexN/A2.952.35DBVTDBV TechnologiesN/A0.720.72NUVBNuvation BioN/A9.019.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%CDXCChromaDex15.41%DBVTDBV Technologies71.74%NUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%CDXCChromaDex9.64%DBVTDBV Technologies1.44%NUVBNuvation Bio29.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.42 million212.18 millionOptionableCDXCChromaDex12077.75 million69.02 millionOptionableDBVTDBV Technologies8027.39 million27.00 millionOptionableNUVBNuvation Bio60340.26 million238.42 millionOptionableDBVT, CDXC, NUVB, and ABCL HeadlinesRecent News About These CompaniesNuvation Bio Inc. (NUVB) latest stock news and headlines - Yahoo FinanceJuly 2, 2025 | uk.finance.yahoo.comNuvation Bio (NYSE:NUVB) Stock Price Up 8% - Time to Buy?June 30, 2025 | marketbeat.comJMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch PlansJune 29, 2025 | msn.comNuvation Bio (NYSE:NUVB) Receives Market Outperform Rating from JMP SecuritiesJune 26, 2025 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Sees Strong Trading Volume - Here's What HappenedJune 25, 2025 | marketbeat.comNuvation Bio's (NUVB) "Market Outperform" Rating Reaffirmed at JMP SecuritiesJune 25, 2025 | marketbeat.comRBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy RatingJune 24, 2025 | msn.comNuvation Bio jumps after insiders purchase shares worth over $1.1MJune 20, 2025 | msn.comNuvation Bio (NYSE:NUVB) Shares Gap Up - Here's WhyJune 20, 2025 | marketbeat.comFounder of Nuvation Bio David Hung Buys More StockJune 20, 2025 | finance.yahoo.comNuvation Bio price target lowered to $6 from $10 at RBC CapitalJune 18, 2025 | investing.comNuvation Bio: A Justified Fall Based On Post-Marketing RequirementsJune 18, 2025 | seekingalpha.comRoyal Bank of Canada Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock PriceJune 17, 2025 | marketbeat.comNuvation Bio (NYSE:NUVB) Shares Gap Down - Time to Sell?June 16, 2025 | marketbeat.comOnco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.June 16, 2025 | globenewswire.comNuvation Bio price target maintained at $6 by Citizens JMPJune 14, 2025 | investing.comNuvation Bio’s SWOT analysis: FDA approval boosts stock prospectsJune 14, 2025 | investing.comNuvation Bio (NYSE:NUVB) Downgraded to "Sell" Rating by Wall Street ZenJune 14, 2025 | marketbeat.comNuvation Bio Stock Short Interest Report | NYSE:NUVB | BenzingaJune 13, 2025 | benzinga.comUS FDA approves Nuvation Bio's rare lung cancer drugJune 13, 2025 | msn.comNuvation Bio (NYSE:NUVB) Trading Down 5.5% - Here's What HappenedJune 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDBVT, CDXC, NUVB, and ABCL Company DescriptionsAbCellera Biologics NASDAQ:ABCL$3.80 +0.06 (+1.47%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$3.78 -0.02 (-0.53%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.ChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.DBV Technologies NASDAQ:DBVT$11.54 +1.24 (+12.03%) Closing price 07/3/2025 01:03 PM EasternExtended Trading$11.59 +0.05 (+0.43%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Nuvation Bio NYSE:NUVB$2.08 +0.04 (+1.71%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$2.07 -0.02 (-0.72%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.